Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
December 10, 2001
- 9 NCEs Including Glivec, Rebetol Listed
December 10, 2001
- MEDICAL DEVICE NEWS IN BRIEF
December 10, 2001
- Bayer Medical: Smear Sampling, Staining Device ADVIA S60
December 3, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -3-
December 3, 2001
- Bayer Medical: Myocardial Infarction Marker Kit
December 3, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
December 3, 2001
- Shionogi Ties Up with SRL in Lab Test Business
December 3, 2001
- Banyu: Nu-lotan Boosts Sales, but Profits Down due to Loss Caused by Securities Sale
December 3, 2001
- Korosho Requires Inspections of Hollow-fiber Dialyzers
December 3, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
December 3, 2001
- GEYMS: Top of the Line LOGIQ Ultrasound Device Introduced
December 3, 2001
- Listed Wholesalers' Profits Plummet Despite Increases in Sales
December 3, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 3, 2001
- BUSINESS NEWS IN BRIEF
December 3, 2001
- WORLD NEWS IN BRIEF
December 3, 2001
- Aiming at \2 Trillion Sales in FY2009: Kuraya Sanseido President
December 3, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 3, 2001
- Kissei Withdraws Additional Indication Application for Rizaben
December 3, 2001
- Nippon Roche, GSK/IPF Hold Seminars on Influenza
December 3, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…